Table 1 Characteristics of septic shock patients treated or not with aminoglycosides before and after matching on the propensity score
From: Aminoglycosides for the treatment of septic shock: a propensity-based study
Variables | Before matching | p | After matching | p | ||
|---|---|---|---|---|---|---|
Aminoglycosides (n = 616) | No aminoglycosides (n = 424) | Aminoglycosides (n = 348) | No aminoglycosides (n = 348) | |||
Age, years | 70.2 (58.2–79.7) | 67.5 (56.5–77.5) | 0.02 | 70.2 (56.6–79) | 66.9 (55.9–76.9) | 0.06 |
Male gender | 386 (62) | 278 (65) | 0.36 | 227 (65) | 228 (65) | 1 |
Immunosuppression | 249 (40) | 135 (31) | 0.005 | 127 (37) | 105 (30) | 0.09 |
Neutropenia | 91 (15) | 38 (9) | 0.006 | 41 (12) | 30 (9) | 0.21 |
Characteristics on ICU admission | ||||||
SAPS2, points | 70 (53–87) | 65 (51–80) | 0.002 | 68 (52–85) | 65 (51–80) | 0.17 |
Source of infection | 0.29 | |||||
Lung | 241 (39) | 248 (58) | < 0.001 | 169 (48) | 202 (58) | |
Digestive | 82 (13) | 46 (11) | 44 (13) | 37 (11) | ||
Urinary | 101 (17) | 24 (5) | 24 (7) | 17 (5) | ||
Skin and soft tissue | 57 (9) | 24 (5) | 30 (9) | 23 (7) | ||
Catheter | 33 (5) | 12 (3) | 13 (4) | 9 (3) | ||
Others | 29 (5) | 23 (5) | 20 (6) | 21 (6) | ||
Unknown | 73 (12) | 47 (11) | 48 (14) | 39 (12) | ||
Microbiological documentation | 419 (68) | 263 (62) | 0.05 | 226 (65) | 228 (66) | 0.93 |
Bacteremia | 241 (39) | 106 (25) | < 0.001 | 114 (33) | 90 (26) | 0.055 |
Microorganisms | ||||||
Gram-negative bacteria | 290 (47) | 131 (31) | < 0.001 | 137 (60) | 102 (45) | 0.003 |
Gram-positive bacteria | 120 (19) | 120 (28) | 85 (38) | 114 (50) | ||
Fungi | 9 (1) | 10 (2) | 4 (2) | 11 (4.5) | ||
Mycobacteria | 0 (0) | 2 (0.5) | 0 (0) | 1 (0.5) | ||
Biological findings | ||||||
Serum protein level, g/L | 56 (49–64) | 60 (53–68) | < 0.001 | 58 (51–66) | 60.5 (53–68) | 0.009 |
Serum creatinine level, μmol/L | 144 (95–228) | 131 (80–201) | 0.007 | 139 (84–225) | 132 (82–206) | 0.23 |
ICU management at day 1 | ||||||
First 24-h fluid balance, mL | 2485 (1000–4378) | 2088 (717–3552) | < 0.001 | 2358 (900–4200) | 2136 (900–3700) | 0.18 |
Renal replacement therapy at day 1 | 110 (18) | 59 (14) | 0.13 | 58 (17) | 52 (15) | 0.60 |
Norepinephrine amount at day 1, mg | 28.2 (8.5–73) | 18.2 (5.3–48.2) | < 0.001 | 25 (5.8–55.2) | 20 (6.9–50.3) | 0.20 |
Aminoglycosides treatment | ||||||
Administration prior to ICU admission | 116 (19) | 50 (14) | ||||
Amikacin | 379 (62) | 218 (63) | ||||
Loading dose, mg/kg | 19.7 (17.2–23.6) | 20 (17–24) | ||||
Recommended loading dose | 78 (21) | 51 (23) | ||||
Median Cpeak, mg/L * | 52.4 (34.8–61) | 47.2 (35.7–60.6) | ||||
Recommended target | 36 (33) | 18 (30) | ||||
Gentamicin/Tobramycin | 237 (38) | 130 (37) | ||||
Loading dose, mg/kg | 4.7 (4.2–6.1) | 5.4 (4.2–6) | ||||
Recommended loading dose | 63 (27) | 40 (30) | ||||
Median Cpeak, mg/L* | 15.2 (10.6–19.9) | 14.7 (10.4–19.6) | ||||
Recommended target | 4 (6) | 0 (0) | ||||
Overall ICU management | ||||||
Invasive mechanical ventilation | 500 (81) | 366 (86) | 0.03 | 292 (84) | 305 (88) | 0.19 |
Renal replacement therapy | 319 (52) | 162 (38) | < 0.001 | 179 (51) | 131 (38) | < 0.001 |
Outcomes | ||||||
Creatininemia at day 3, μmol/L | 85 (50–153) | 85 (51–152.2) | 0.71 | 91 (54–158.5) | 89.5 (54.75–158.2) | 0.86 |
Creatininemia at discharge, μmol/L | 90 (58–173) | 83 (54.75–144.2) | 0.019 | 92.5 (58–177) | 79.5 (54–137.5) | 0.024 |
End-of-life decision | 136 (22) | 117 (28) | 0.047 | 52 (15) | 69 (20) | 0.11 |
7-day mortality | 142 (23) | 75 (18) | 0.03 | 65 (19) | 51 (15) | 0.12 |
In-ICU mortality | 229 (37) | 140 (33) | 0.19 | 126 (36) | 103 (29) | 0.076 |